Anavex Life Sciences Corp (AVXL)

[apostrophe]

re: Motley Fool article

Once again they live up to their name. I notice they end with a pitch for their current "next big thing", which are invariably duds. Better hurry they've only been pushing it for months now. :)

Their target audience seems to be dumb investors. Dumb advice for dumb investors.

The author "He genuinely enjoys cutting through the industry's complexities to help everyday investors make better decisions. " See what I mean? :)

Odd that they would single out AVXL for what amounts to what would be a hit piece for them. Venom isn't really their thing but, big errors of omission in that Anavex is poised to displace Aricept which has a multi-billion dollar market in just the AZ indication and are already getting grants for other indications. Works at least as good with a proven superior safety profile. Considering the FDA approved poisons on the market that pass for "standard of care" treatments for incurable diseases, FDA approval is a foregone conclusion.

100 million authorized shares "means everything" ?! What a crock! It means nothing. Outstanding shares and market cap are actually informative. AVXL has been frugal about issuing shares. We have 36 million and about 40 million fully diluted.

Then he cites cancer bio-techs for comparison. Apples and oranges. How about an actual direct competitor? AXON has 100 million outstanding shares. In spite of the fact that it's a dead company and just hasn't realized it yet, it's about to lose it's main market, share price is on it's way down, but it's still around $15 a share. And this is the author's "worst case" of 100 million shares.

Do the math. Oh, I forgot. We're too "dumb" for that. :)